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Ceramide and diacylglycerol (DAG) may be involved in the early phase of insulin resistance but data are inconsistent in man.
We evaluated if an increase in insulin sensitivity after endurance training was accompanied by changes in these lipids in skeletal
muscle. Nineteen first-degree type 2 diabetes Offsprings (Offsprings) (age: 33.1±1.4 yrs; BMI: 26.4±0.4 kg/m2) and sixteenmatched
Controls (age: 31.3±1.5 yrs; BMI: 25.3±0.7 kg/m2) performed 10 weeks of endurance training three times a week at 70% of VO
2
max
on a bicycle ergometer. Before and after the intervention a hyperinsulinemic-euglycemic clamp and VO
2
max test were performed
and muscle biopsies obtained. Insulin sensitivity was significantly lower in Offsprings compared to control subjects (𝑝 < 0.01)
but improved in both groups after 10 weeks of endurance training (Off: 17 ± 6%; Con: 12 ± 9%, 𝑝 < 0.01). The content of muscle
ceramide, DAG, and their subspecies were similar between groups and did not change in response to the endurance training except
for an overall reduction in C22:0-Cer (𝑝 < 0.05). Finally, the intervention induced an increase in AKT protein expression (Off:
27 ± 11%; Con: 20 ± 24%, 𝑝 < 0.05). This study showed no relation between insulin sensitivity and ceramide or DAG content
suggesting that ceramide and DAG are not major players in the early phase of insulin resistance in human muscle.
1. Introduction
The 21st century faces a major health challenge worldwide as
the prevalence of insulin resistance (IR) and type 2 diabetes
(T2D) has amplified extensively along with obesity [1, 2].
In obesity, lipid overload leads to increased levels of
both plasma free fatty acids (FFA) and intramyocellular
triglyceride (IMTG) and the latter has shown a negative
correlation with insulin sensitivity [3, 4]. Similar to the obese
condition, also healthy lean first-degree relatives of type 2
diabetic patients exhibit higher plasma fatty acid and IMTG
concentration and a lower insulin sensitivity [4, 5]. There
is at present no evidence for a causal link between IMTG
and insulin sensitivity, but IMTG may facilitate an increased
content of the bioactive lipids ceramide and diacylglycerol
(DAG) in muscle, which have been suggested to mediate this
link through an effect on insulin signaling. In short, ceramide
is suspected to inhibit AKT phosphorylation by activation
of protein kinase C𝜁 (PKC𝜁) and protein phosphatase 2A
(PP2A), while DAG is thought to activate protein kinase C𝜃
(PKC𝜃), which inhibits insulin receptor substrate 1 [6–10].
Human studies have reported a higher muscle content of
ceramide and lower insulin sensitivity in obese and type 2
diabetic patients compared to lean subjects [3, 11–13]. In line
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Figure 1: Ceramide and DAG metabolism in skeletal muscle. Ceramide is synthesized de novo from palmitoyl CoA and serine.
Reversible reactions produce ceramide from sphingosine, glucosylceramide, ceramide 1-phosphate, and sphingomyelin, respectively.
Conversion of ceramide to sphingomyelin also produces DAG. DAG is further synthesized from monoacylglycerol and from degradation
of triacylglycerol. PC: phosphocholine; SMS: sphingomyelin synthase; MAG: monoacylglycerol; MGAT: monoacylglycerol acyltransferase;
DGAT: diacylglycerol acyltransferase; HSL: hormone-sensitive lipase; ATGL: adipose triglyceride lipase. Proteins marked in bold blue are
analyzed by western blotting.
with this, a highermuscle ceramide content and lower insulin
sensitivity was observed in Offsprings from type 2 diabetic
patients compared to matched Controls [14]. However, in
contrast, no difference in muscle ceramide content was
observed in four groups that was comprised of age and lean
body mass of matched trained, control and IGT subjects, and
type 2 diabetic patients, thus representing markedly different
insulin sensitivities [15]. Similarly, Helge et al. [16] found
no difference in muscle ceramide content in trained versus
untrained and sedentary subjects, respectively, while Chow
et al. found a greater ceramide content in trained subjects
than sedentary subjects [17], highlighting the discrepancy
on ceramide data in human muscle. Also the data on DAG
muscle content in man are somewhat inconsistent, where
some studies reported higher muscle DAG content in obese
andT2Dcompared to lean subjects [13, 14]. In contrast, Amati
et al. [11] found lowermuscleDAGcontent in obese compared
to both lean sedentary subjects and athletes, whereas other
studies showed no difference inmuscleDAGcontent between
lean, obese, and trained subjects [12, 13, 17]. Acute lipid
infusion however increased total DAG content to a higher
extent in lean compared to athletes [17]. In contrast, two
studies from the Bergman group reported lower levels of
DAG in muscle in endurance trained athletes compared with
lean sedentary Controls, obese, and T2D subjects [18, 19].
Ceramide and DAGmetabolism are controlled by several
pathways (Figure 1), and the mechanisms regulating the con-
tent and composition of the subspecies inmuscle are not fully
elucidated. Ceramide can be synthesized de novo by serine
palmitoyl transferase (SPT),which catalyzes the first and rate-
limiting step [20, 21]. Ceramide is converted to sphingosine
by ceramidase and further to sphingosine 1-phosphate (S1P)
by sphingosine kinase (SphK) with both reactions being
reversible [22]. In addition ceramide and phosphocholine
can be reversibly converted to sphingomyelin and DAG by
sphingomyelin synthase (SMS) [22]. In addition, DAG can be
made from degradation of phospholipids or metabolized via
the normal pathways where diacylglyceride acyltransferase
(DGAT) converts DAG and FA to triacylglyceride (TAG)
and conversely hormone-sensitive lipase (HSL) and adipose
triglyceride lipase (ATGL) degrades TAG toDAG and FA and
HSL further to monoacylglyceride and FA [23–25].
Training improves whole body glucose tolerance and
insulin sensitivity in human skeletal muscle [26, 27], but the
effect of training on muscle content of ceramide and DAG is
not clear. Some studies found that training improved insulin
sensitivity and decreased total muscle ceramide and DAG
content and specific subspecies in sedentary overweight and
obese subjects [28–30]. In contrast, we observed similar mus-
cle ceramide content in trained insulin sensitive compared to
untrained impaired glucose tolerant subjects [15]. Similarly,
other groups have observed no changes in muscle ceramide
or DAG content after 12 weeks of training in lean or obese
women [31] and men [32]. Overall, there is conflicting and
inconsistent data on both the basal content and the effect of
training on muscle ceramide and DAG content in man and
there is very limited data on the effects on the regulatory
pathways in man.
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Therefore, we aimed to study the influence of training
and genetic susceptibility to T2D on muscle ceramide and
DAG content and the regulatory pathways. Based on the
inconsistent data available, we wanted to contribute with new
knowledge in this area in order to elucidate the role of muscle
ceramide and DAG in insulin resistance and type 2 diabetes.
2. Methods
2.1. Subjects. Nineteen first-degree Offsprings of type 2
diabetic patients (Offsprings) and sixteen Controls were
included in the study.The inclusion was based on availability
of muscle tissue before and after training from the full study
group of twenty-nine and nineteen subjects, respectively,
from a former study [33]. In brief, subjects were recruited
at the outpatient clinic at Medical Department M at Aarhus
University Hospital, Denmark, and through parents formerly
diagnosed with T2D. Furthermore, some Offspring subjects
and all the Controls were recruited through advertisements
in local newspapers. None of the subjects were related.
The subjects were matched based on the following criteria:
Caucasian inheritance, 20–50 years old, body mass index
(BMI) < 30 kg/m2, VO
2
max < 50mL⋅min−1⋅kg−1, normal
glucose tolerance, healthy and sedentary lifestyle, and not
engaging in regular physical activity. The score of habitual
activity level measured by Baecke questionnaire was similar
between the groups [33]. The subjects were not allowed to
take any form of prescribed medicine on regular basis. The
Offspring and Control groups were matched by age, gender,
and BMI and the Offsprings did not differ from the Controls
metabolically in fasting plasma insulin, nonesterified fatty
acids, or glucose. However, the Offsprings had a higher level
of fasting plasma C-peptide [33].
The subjects gave written consent to participate in the
study. The study was approved by the local committee of the
county of Aarhus, Denmark, and the study complies with
The Declaration of Helsinki.The data for the full study group
describing the basic characteristics and the intervention has
been published previously [33].
2.2. Experimental Design. The design and experimental pro-
cedures of the study have previously been described in detail
and will here only be outlined in brief [33].
2.3. Training Protocol. The training intervention was per-
formed over a 10-week period with three sessions a week.
Each session consisted of 45min. of nonsupervised aerobic
exercise where the subjects were instructed to aim for a heart
rate corresponding to 70% of their VO
2
max.The exercise was
performed on a bicycle ergometer at a local fitness center or
on a provided bicycle ergometer at home. After five weeks of
training, the VO
2
max was measured and the exercise work
load adjusted. The adjustments were similar between groups
and negligible.
2.4. Intervention. Prior to the 10-week training intervention,
a maximal exhaustive incremental test on a bicycle ergome-
ter and a submaximal test admodum, Astrand et al. [34],
were performed. The highest test result was selected as the
baseline VO
2
max. The exercise test protocol was performed
both before and after the intervention. Insulin sensitivity
was measured by a hyperinsulinemic-euglycemic clamp and
muscle biopsies obtained at initiation and again 3-4 days after
the last exercise session. In addition, a standard 2-hour oral
glucose tolerance test (OGTT) was carried out prior to the
intervention and repeated 4-5 days before the last exercise
bout.
2.5. Hyperinsulinemic-Euglycemic Clamp. After an overnight
fast, the subjects rested in bed for 150min. After 120min.,
muscle biopsies were obtained. Insulin was infused starting
at 150min. at a rate of 1.0mU⋅kg−1⋅min−1 and plasma glucose
was kept at 5mM by glucose infusion (200mg/L). Steady
state was achieved after 270–300min. (120–150min. into the
clamp) and the average glucose infusion rate was taken as
the insulin stimulated glucose uptake (ISGU). Energy expen-
diture and glucose and lipid oxidation rates were measured
between 120–150 and 270–300min., respectively, using an
open-circuit ventilation hood.
2.6. Muscle Biopsies. Muscle biopsies were taken in vastus
lateralis of the quadriceps muscle by a Bergstrom needle
(5mm) after injection of local anaesthesia (10% lidocaine) in
the skin and percutaneous region. The biopsy was divided
and immediately put into −80∘C liquid nitrogen or mounted
with Tissue-Tek (Sakura Finetek, Zoeterwoude, Netherlands)
and frozen in isopentane cooled in liquid nitrogen. The
samples were subsequently stored at −80∘C for analysis. Prior
to analyses, visible blood and fat were removed from the
biopsies.
2.7. Bioactive Lipid Analysis. Ceramides and diacylglyc-
erols were measured according to the methods described
by Blachnio-Zabielska et al. [35, 36]. Briefly, lipids were
extracted from ∼20mg of tissue by the use of the extrac-
tion mixture composed of isopropanol : water : ethyl acetate
(35 : 5 : 60; v : v : v). Quantitative measurement of ceramides
and diacylglycerols was made using an Agilent 6460 triple
quadrupole mass spectrometer. Both ceramides and dia-
cylglycerols were analyzed using positive ion electrospray
ionization (ESI) source with multiple reaction monitoring
(MRM). The chromatographic separation was performed
using an Agilent 1290 Infinity Ultra Performance Liquid
Chromatography (UPLC). The analytical column was a
reverse-phase Zorbax SB-C8, 2.1 × 150mm, 1.8 𝜇m (Agilent,
Santa Clara, CA). Chromatographic separation was con-
ducted in binary gradient using 2mM ammonium formate,
0.15% formic acid in methanol as Solvent A, and 1.5mM
ammonium formate; 0.1% formic acid in water as Solvent
B at the flow rate of 0.4mL/min. C17:0-ceramide and 1,3-
dipentadecanoyl-rac-glycerol (Avanti Polar Lipids, Alabaster,
AL) were used as internal standards for ceramides and
diacylglycerols, respectively. The HPLC grade methanol and
water as well as formic acid and ammonium formate were
obtained from Sigma-Aldrich (St. Louis, MO).
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2.8. Western Blot. To measure the content of proteins
involved in sphingolipid metabolism or insulin signaling
western blotting was performed as described previously [37]
with modifications. In brief, muscle biopsies were freeze-
dried for 48 hours at−40∘Cat<0.5mBar followed by 1 hour of
equilibration to room temperature (RT) at maintained pres-
sure. ∼20mg tissue (wet weight) was dissected and homog-
enized in 400𝜇L cold Radio-Immunoprecipitation Assay
buffer added protease and phosphate inhibitors. Protein con-
centration was measured in triplicate using a bicinchoninic
acid (BCA) assay. 10 𝜇g of protein per 13 𝜇L homogenate was
diluted in Laemmli buffer and MilliQ water. The tubes were
heated and the samples and a calibrator (5 𝜇g), a molecular
weight marker (Magicmark, XP western std. (2 𝜇L), andHigh
RangeRainbowmolecularweightmarker (2𝜇L))were loaded
and separated on 26 wells 12% Criterion TGX Stain-Free
polyacrylamide SDS gels at 100V.The gels were activated and
a 1 sec. image was taken with LAS 4000 image analyzer (GE
Healthcare, Little Chalfont, UK). The gels were transferred
to an ethanol activated polyvinylidene fluoride (PVDF)
membrane (0.2 𝜇m pores, Bio-Rad, Copenhagen, Denmark)
using semidry blotting at 25V in 7min. A 1 sec. image was
taken with UV light of the membranes with the proteins
transferred.
The membranes were blocked in 5% skimmed milk or
5% bovine serum albumin (BSA) diluted in Tris-buffered
saline (TBS) for 1 or 1.5 hours at RT. The membranes
were incubated overnight with primary antibody: antiserine
palmitoyl transferase (SPT) 1 : 2000 (ab23696, Abcam, Cam-
bridge, UK), antisphingomyelin synthase 2 (SMS2) 1 : 2000
(ab103060, Abcam), antisphingosine kinase 1 (SphK1) 1 : 1000
(ab37980, Abcam), and anti-AKTpan 1 : 1000 (number 4691,
(C67E7), Cell Signaling, Massachusetts, USA) all in 5%
skimmed milk, and anti-p-AKT (ser473) 1 : 1000 (number
4060, (D9E), Cell Signaling), antiprotein kinase C𝜃 (PKC𝜃)
1 : 2000 (ab110728, Abcam), and anti-p-PKC𝜃 (ser676) 1 : 2000
(ab131479, Abcam) all in 5% BSA. The secondary antibody
used was polyclonal goat anti-rabbit horseradish peroxidase
conjugated (number 7074S, Cell Signaling) 1 : 2000 diluted
in 5% skimmed milk or 5% BSA in TBS in line with the
primary antibody. The membranes were washed 2 × 5min.
with TBS added 0.05% Tween 20 followed by 1 × 5min. with
TBS after incubation with primary and secondary antibody,
respectively. The blots were incubated for 1min. with ECL
detection reagents (Amersham western blotting detection
reagents, GEHealthcare,UK) and the proteins visualized.The
UV images of the membranes and the images of the proteins
of interest were quantified using ImageQuant TL software
version 7.0 (GE Healthcare). The intensity of each band of
interest was normalized to total protein measured by Stain-
Free fluorescence (UV picture after transfer) as described
previously [38]. To compare the samples loaded on different
gels, all samples were quantified relative to the calibrator
(pool of all samples) which was loaded on all gels in 2-3 lanes.
2.9. Fiber Type Distribution. Muscle fiber type distribution
was performed and analyzed using myofibrillar ATPase
histochemistry as previously described [33].
2.10. Statistical Analyses. All data are presented as means ±
SEM. Comparison of the Control and Offspring groups and
the effect of the intervention were analyzed by a two-way
analysis of variance (ANOVA) with repeated measurements
and Holm-Sidak post hoc test. Correlations were carried
out using Pearson Correlation Coefficient. All analyses were
performed using Sigma Plot 12.5.
3. Results
The compliance of the subjects to the exercise program was
similar between the groups according to number of training
sessions performed, as previously described [33]. Maximal
oxygen uptake, body weight, insulin sensitivity, and insulin
basal during the clamp were reported in a prior paper [33],
but they are also included here with the values of the subset of
persons that are included in this paper. Ten weeks of training
induced a decrease (𝑝 = 0.003) in body weight of 1.1 ±
0.3 kg (Table 1), which was independent of group and gender.
Prior to the experiment, VO
2
max was not different between
the Control and Offspring groups, and, after the training,
VO
2
max was increased (𝑝 < 0.001) similarly in the groups
by 16 ± 2% (Table 1). The insulin sensitivity, measured as𝑀-
value, was higher (𝑝 = 0.008) in the Control compared to
the Offspring group and after 10 weeks of exercise training
it was increased (𝑝 = 0.008) by 17.0 ± 5.9% and 11.8 ±
9.2% in Offspring and Control, respectively (Table 1). Insulin
sensitivity did not differ (𝑝 = 0.484) between males and
females (data not shown).
As described previously [33] a positive correlation was
found between insulin sensitivity and VO
2
max at baseline
and after the exercise training intervention in the Control
group.
3.1. Muscle Protein. The muscle protein content of basal
SPT, SMS2, SphK1, PKC𝜃, P-PKC𝜃ser676 and P-AKTser473 did
not differ between the groups and was not affected by the
intervention (Figure 2). Basal AKTprotein expression did not
differ between the groups but increased (𝑝 = 0.03) in both
groups after the intervention (Figure 2(b)). AKTser473 did not
correlate with insulin sensitivity at basal or as % change after
the intervention (Figure 3(d)).The individual percent change
in SMS2 protein expression after the training intervention
was positively correlated (𝑝 = 0.006, 𝑅 = 0.582, 𝑛 = 21)
with the change in SphK1.
3.2. Muscle Bioactive Lipids. The total muscle ceramide con-
tent and the content of ceramide subspecies were not different
between theOffspring andControl group or between genders
(Table 2). There was no difference in C16:0-Cer content
between the groups and no main effect on the change in
C16:0-Cer content, but a borderline significant training ×
group interaction (𝑝 = 0.082) was found. Due to lack
of a significant interaction we could not further test for
differences (Table 2), but a numerical reduction of 33% was
observed in the Control group and 3.2% in the Offsprings.
The total ceramide content was not changed (𝑝 = 0.27)
in response to 10 weeks of training in either of the groups
Journal of Diabetes Research 5
Table 1: Subject characteristics, maximal oxygen uptake, and insulin sensitivity before and after 10 weeks of endurance training in T2D
offspring and matched controls.
Characteristics
Control Offspring
(𝑛 = 16) (𝑛 = 19)
Pre Post Pre Post
Gender (M/F) 10/6 12/7
Age (yrs) 31.3 ± 1.5 33.1 ± 1.4
Weight (kg) 80.6 ± 3.7 79.2 ± 3.5∗∗ 83.7 ± 1.9 82.8 ± 1.8∗∗
BMI (kg/m2) 25.3 ± 0.7 24.9 ± 0.7 26.4 ± 0.4 26.1 ± 0.4
VO
2
max (mL/min) 3301 ± 198 3768 ± 266∗ 3222 ± 179 3734 ± 208∗
VO
2
max (mL/min/kg) 41.1 ± 1.6 47.4 ± 2.2∗ 38.3 ± 1.6 44.8 ± 2.0∗
𝑀-value (mg/min/kg) 7.58 ± 0.76 8.47 ± 0.73∗∗† 5.35 ± 0.37 6.27 ± 0.52∗∗
Fiber type I% 46.3 ± 4.0 45.3 ± 3.4 46.3 ± 4.2 44.8 ± 4.1
Fiber type IIA% 37.1 ± 3.8 38.4 ± 2.5 34.7 ± 2.4 40.5 ± 2.7
Fiber type IIX% 16.6 ± 2.1 16.3 ± 2.7 18.9 ± 3.4 14.7 ± 2.4
The present data are based on subsample of previously published data [33]. Data are mean ± SEM. ∗Pre versus post main effect (𝑝 < 0.001);
∗∗Pre versus post main effect (𝑝 < 0.01); †Con. versus Off. (𝑝 = 0.008).
Table 2: Muscle ceramide subspecies and total content before and after 10 weeks of endurance training in T2D offsprings and matched
controls.
Ceramide Control(𝑛 = 16)
Offspring
(𝑛 = 19) 𝑝 value
Subspecies Pre Post %Δ Pre Post %Δ Trainingmain effect
Training ×
group
interaction
C14:0 0.0052 ±
0.0010
0.0046 ±
0.0007
−11.5 0.0042 ±
0.0009
0.0057 ±
0.0011
35.1 0.335 0.268
C16:0 0.41 ± 0.06 0.27 ± 0.04 −33.2 0.38 ± 0.09 0.37 ± 0.05 −3.22 0.251 0.082
C18:0 5.67 ± 0.36 5.55 ± 0.68 −2.08 6.06 ± 0.58 6.04 ± 0.27 −0.28 0.830 0.426
C18:1 0.12 ± 0.02 0.11 ± 0.02 −12.4 0.11 ± 0.01 0.11 ± 0.01 5.80 0.670 0.292
C20:0 0.046 ± 0.014 0.031 ± 0.004 −32.0 0.029 ± 0.003 0.029 ± 0.003 −0.01 0.384 0.286
C22:0 1.63 ± 0.11 1.39 ± 0.14∗ −14.8 1.38 ± 0.08 1.29 ± 0.08∗ −6.93 0.017∗ 0.294
C24:0 0.0041 ±
0.0008
0.0036 ±
0.0016
−11.5 0.0033 ±
0.0007
0.0044 ±
0.0008
35.1 0.335 0.268
C24:1 3.81 ± 0.21 3.84 ± 0.29 0.94 3.58 ± 0.18 3.27 ± 0.24 −8.71 0.251 0.323
Mean %Δ −14.6 ± 4.4 7.11 ± 6.3
Total cer. 11.7 ± 0.6 11.2 ± 1.1 −4.27 11.6 ± 0.8 11.1 ± 0.5 −4.31 0.272 0.579
Data are means ± SEM. All data are given as pmol/mg wet weight. The statistics are based on log 10 due to failed normality testing. ∗Pre versus post main
effect, (𝑝 = 0.017). The% delta calculated as the relative change from baseline.
(Table 2). However, C22:0-Cer was significantly and similarly
reduced (𝑝 = 0.02) in the two groups after the intervention
(Table 2). The content of total ceramide (𝑝 = 0.49, 𝑅 =
−0.124) or C22:0-Cer (𝑝 = 0.15, 𝑅 = −0.259) did not
correlate with insulin sensitivity before (Figures 3(a) and
3(b)) or after (figure not shown) the endurance intervention.
The calculated individual% differences in total ceramide (𝑝 =
0.37, 𝑅 = −0.161) and C22:0-Cer (𝑝 = 0.20, 𝑅 = −0.230)
content across the training period were not correlated with
the percent change in insulin sensitivity (Figures 3(a) and
3(b)). The degree of ceramide saturation did not change in
response to the training and did not correlate with insulin
sensitivity. No correlations were found either between the %
change in content of any of the proteins measured or total
ceramide content.
The total DAG content and the content of the individual
DAG subspecies in both Offspring and Control subjects
were not significantly influenced by the training intervention
(Table 3). Moreover, there was no difference between the
two groups in muscle content of total DAG or individual
subspecies (Table 3) or between genders. Furthermore, the
total content of DAG measured in muscle was not correlated
with insulin sensitivity at baseline (𝑝 = 0.67, 𝑅 = −0.078),
after the intervention (figure not shown), or across the
intervention (𝑝 = 0.22, 𝑅 = −0.220), calculated as the
individual % differences (Figure 3(c)). Similarly, the DAG
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Figure 2: Protein expression including representative blots in Offsprings of type 2 diabetic patients and matched Controls before and after
10 weeks of training intervention. Proteins presented are involved in (a) ceramide and DAGmetabolism and (b) insulin signaling. Pre: black
bars; Post: grey bars. ∗: main effect of the training intervention in Offspring and Control subjects (𝑝 = 0.03, 𝑛 = 21).
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Figure 3: Continued.
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Figure 3: Muscle content of (a) C22:0-Cer, (b) total ceramide, (c) total DAG, and (d) P-AKTser473 protein expression as function of insulin
sensitivity at basal and the percent change after 10 weeks of endurance training in type 2 diabetic Offsprings (e) and matched Controls (I).
Table 3: Muscle diacylglycerol subspecies before and after 10 weeks of endurance training in T2D offspring and matched controls.
DAG Control(𝑛 = 16)
Offspring
(𝑛 = 19) 𝑝 value
Subspecies Pre Post %Δ Pre Post %Δ Trainingmain effect
Training ×
group
interaction
16:0/16:0 152 ± 25 115 ± 14 −24.1 147 ± 21 140 ± 19 −5.01 0.291 0.480
16:0/18:0 213 ± 28 189 ± 26 −11.6 240 ± 42 239 ± 38 −0.48 0.695 0.720
16:0/18:1 211 ± 27 194 ± 24 −7.95 268 ± 40 260 ± 37 −3.00 0.666 0.940
16:0/18:2 33.9 ± 4.5 28.8 ± 3.5 −15.2 38.8 ± 6.1 35.3 ± 3.9 −9.05 0.338 0.855
18:0/18:1 24.4 ± 3.3 24.3 ± 2.9 −0.22 30.3 ± 3.6 29.6 ± 4.3 −2.37 0.911 0.923
18:1/18:1 74.4 ± 10.8 69.7 ± 9.7 −6.32 89.9 ± 13.9 87.1 ± 12.9 −3.16 0.729 0.932
18:1/18:2 50.1 ± 7.6 47.5 ± 6.6 −5.29 57.6 ± 8.6 51.1 ± 6.1 −11.3 0.453 0.751
Mean %Δ −10.1 ± 2.9 −4.9 ± 1.6
Total DAG 759 ± 90 668 ± 80 −12.0 872 ± 127 842 ± 114 −3.44 0.495 0.839
Data are means ± SEM. All data are given as pmol/mg wet weight. The statistics for 16:0/18:1 and total DAG are based on log 10 due to failed normality testing.
The% delta calculated as the relative change from baseline.
subspecies or the degree of saturation of DAG (data not
shown) did not correlate with insulin sensitivity at any time
point. The % change in total DAG content was not correlated
with the % change in any of the proteins measured.
3.3. Fiber Type. Fiber type data were reported in a prior paper
[33], but they are also included here for the subset of persons
that are included. The muscle fiber type distribution did
not differ between the groups or in response to the exercise
training intervention (Table 1).
4. Discussion
A major finding of this study was that the key proteins
in the regulatory pathways of ceramide and diacylglycerol
metabolism were not different between Offspring of type 2
diabetic patients and matched Control subjects or influenced
by training. In addition, we observed that ceramide and
DAG muscle content and subspecies, except for ceramide
22:0 subspecies, were not affected by 10 weeks of training
in Offspring of type 2 diabetic patients and matched Con-
trol subjects, though a clear training induced increase in
insulin sensitivity and maximal oxygen uptake as well as
increased citrate synthase and cytochrome oxidase activity, as
previously described [33]. Finally, there were no differences
between groups or sex in ceramide and DAG content and
their subspecies.
The observation of no effect of training on total muscle
ceramide andDAG content in the present study is in line with
previous findings, showing no difference in ceramide and
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DAGcontent between lean and obesewomen [31] ormen [32]
after 12 weeks of endurance training or ceramide content after
15 weeks of life style intervention [39], though the training
and lifestyle induced improvement in insulin sensitivity in
these three studies. Yet, Dube´ et al. found a decrease in
ceramide and DAG content in older overweight to obese
subjects in response to 16 weeks of endurance training [28,
29]. In addition, a recent study by Coen et al. found a lower
ceramide content after gastric bypass induced weight loss and
exercise compared to just gastric bypass induced weight loss
[40]. Evidently, the available data on the effect of training
on muscle bioactive lipid content are very inconsistent and
an explanation for this is not readily apparent. We have
previously demonstrated that ceramide content was higher in
type I than type II muscle fibers in man [41, 42] and therefore
fiber type distribution, which often varies between lean and
obese [28, 43] and which in vastus lateralis demonstrate
rather large heterogeneity [44], may explain some of this
inconsistency. The total content of ceramide and DAG does
not decrease significantly in response to endurance training;
however, it could also be speculated that small nonsignificant
changes may be biologically relevant. The lack of training
induced changes could be explained by a low power, but
previous studies have reported changes with much fewer
subjects included [28, 29]. Furthermore, it should be kept
in mind that insulin sensitivity may be affected by mito-
chondrial dysfunction, impaired beta oxidation, and ROS
emission as well as inflammation and this could potentially
mask a possible relationship between ceramide andDAG and
insulin sensitivity. It could further be emphasized that the
total content of ceramide andDAG inmuscle is not important
in insulin resistance and that we should turn our attention
to specific subspecies or specific localization. In the present
study, all the ceramide and DAG subspecies were unchanged
except for C22:0-Cer, where we found a significant reduction,
yet the change was not correlated with the improvement
in insulin sensitivity measured by the euglycemic hyperin-
sulinemic glucose clamp technique. Prior studies [29, 40]
have not reported C22:0-Cer as a subspecies suspected to
affect insulin sensitivity so the observed reduction in C22:0-
Cer content may not be of great importance in this context.
The C16:0-Cer subspecies has been associated with reduced
insulin sensitivity in some studies [12, 29], while others do not
find a link [11].We did not detect significant changes inC16:0-
Cer after endurance training, but a borderline significant
(𝑝 = 0.082) interaction between the groups indicates that
the 33% numerical reduction in C16:0-Cer in the control
group could be significant andmay be of biological relevance.
Coen and colleagues recently reported changes in specific
ceramide species when gastric bypass induced weight loss
was combined with exercise [40] and the same group also
observed differences in ceramide and DAG subspecies in a
cross-sectional study of trained versus untrained [11] and
with diet induced weight loss and exercise [29]. Reductions
in specific ceramide and DAG subspecies have furthermore
been found after 8 weeks of endurance training intervention
in obese subjects including C16:0-Cer [30].The inconsistency
in the exercise induced effect on the content of total ceramide
and subspecies is not readily explainable, but it is indeed
possible that specific localization of subspecies within the
cell may exert a modulatory effect on insulin signaling as
recently suggested for DAG species [18, 45]. A study by Boon
et al. reported that induction of insulin resistance in mice
by ceramide infusion only increased ceramide in the plasma
membrane of the myocyte supporting this hypothesis [46].
However, the actual mechanisms for this in man remain
largely unknown and further work is needed to confirm and
outline this.
We found a small but significant reduction in bodyweight
which could potentially have affected insulin sensitivity and
metabolism. However, it is a relatively small change and,
taking day to day variation into account, this probably does
not play an important role in insulin sensitivity.
As published in the initial study [33], Offsprings had
lower insulin sensitivity than Controls consistent with find-
ings in other studies [14, 47, 48]. If ceramide and/or DAG in
muscle plays a role in the early phase of insulin resistance,
we would have expected to find higher levels in the Offspring
group, and this was not the case. In contrast, Straczkowski
et al. reported that ceramide content was increased in type
2 diabetes offspring subjects [14]. These contradicting results
may in part be explained by the offspring subjects displaying
different metabolic conditions and developmental stages of
insulin resistance. Furthermore, it should be noted that not
all type 2 diabetes Offsprings develop insulin resistance
[4, 49].
The similar protein expression of the three key enzymes
in ceramide and DAG metabolism agrees well with the
lack of differences in ceramide and DAG total content and
their subspecies between the groups and in response to
the training. However, the activity of these enzymes may
not only depend on the expression level but could also be
regulated by posttranslational modification or association
with regulatory proteins.The content of SMS2 and SphK1 was
not significantly affected by training, but there was a strong
positive correlation between the percent change in expression
of SMS2 and SphK1, suggesting that the protein expression of
the pathway is linked.
We found no differences in basal AKT protein expression
and p-AKTser473 between Offsprings and Controls which
is consistent with studies demonstrating no difference in
expression of AKT and p-AKTser473 between lean, obese
insulin resistant, and nondiabetic insulin resistant Offsprings
of type 2 diabetic patients and type 2 diabetic patients [3,
50, 51]. In contrast, one study observed a lower basal AKT
protein content in diabetic patients compared to Controls
[52]. Studies have reported an increase in basal AKT protein
expression in response to aerobic training of three to ten
weeks in duration in healthy males, control, obese, and T2D
subjects [52, 53]. These findings agree well with our results
and are also in concordance with the observed improvement
in insulin sensitivity. Protein expression of p-AKTser473 in
muscle has shown to increase in response to insulin stimula-
tion in muscle in healthy, obese, and type 2 diabetic subjects,
but whether the insulin stimulated p-AKTser473 content differ
between subjects displaying different metabolic conditions is
not clear [51–54]. The basal content of p-AKTser473 has been
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reported not to change in response to exercise training, while
it is a bit more controversial in the insulin stimulated state
showing an increase or no change [52–54].
In a recent study, Szendroedi et al. reported higher PKC𝜃
activity and total and cytosolic DAG content in obese and
T2D subjects compared to Controls, while membrane DAG
was only increased in T2D [55]. Nevertheless, we found
no differences in PKC𝜃 or p-PKC𝜃ser676 protein expression
between Controls and Offsprings and no training induced
changes either. In agreement with this, Rose et al. showed no
changes in cytosolic or membrane PKC𝜃 protein content in
muscle in young untrained subjects after one bout of exercise
of 40min. at 76±1%of VO
2
peak [56]. If indeedDAG inhibits
insulin signaling by activation of PKC𝜃 as suggested [7, 8, 55],
these findings are well in line with the lack of effects on
DAG content in the present study. Increased plasma fatty
acid content is usually linked to reduced insulin sensitivity
and increased ceramide and DAG synthesis. Montell et
al. found that human cultured cells treated with saturated
FA induced changes in basal glucose uptake and insulin
response that were related to DAG accumulation and PKC
activation [7]. In line with this, lipid infusion was reported
to induce an increase in DAG content and PKC𝜃 activation
in muscle in healthy young males and PKC𝜃 activation was
positively correlated with both plasma FA concentration and
muscle DAG content and negatively correlated with insulin
sensitivity [55]. However, in the present study, we found no
differences in plasma FA concentration, DAG content, or
PKC𝜃 protein expression between Controls and Offsprings
despite reduced insulin sensitivity, and this highlights the
difficulty in comparing results from studies with acute
exposure to lipids with chronic physiological conditions in
human.
The general lack of change in content of proteins mea-
sured involved in insulin signaling except for AKT may
indicate that changes in insulin signaling are not involved
in the training induced improvement in insulin sensitivity.
However, changes in insulin signaling may not exclusively be
explained by the content of the proteins involved but also the
activity of the proteins measured as the membrane to cytosol
ratio.
A possible limitation to this study is that the biopsies
originate from a study performed approximately 10 years
ago, so the biopsies have been stored in −80∘C freezer for a
long period. However, four recently obtained biopsies from
matched patients were applied as control biopsies and thus
analyzed by lipidomics along with the biopsies from this
study. We measured no difference in the values of ceramide
and DAG content from the biopsies of this study compared
to the recently obtained control biopsies. This confirms that
the lipids are highly preserved in the older biopsies and
that the values measured are reliable. Furthermore, our data
indicates that the protein content also remains stable during
the long term freezing period, since we observed similar band
intensity of the specific proteins measured by western blot in
the biopsies from the present study compared with biopsies
from a recently completed study.
5. Conclusion
The total muscle content of ceramide and DAG and their
measured subspecies are not different in first-degree Off-
springs of type 2 diabetic patients compared tomatched Con-
trols. Ten weeks of exercise training improves VO
2
max, insu-
lin sensitivity, andAKTprotein expression in bothOffsprings
and Controls but does not induce any changes in ceramide
or DAG content in line with our hypothesis. We found no
correlation between insulin sensitivity and ceramide or DAG
content, suggesting that ceramide and DAG are not major
players in the early phase of insulin resistance in human
skeletal muscle.
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